Diagnostic and Prognostic Value of Kappa Light Chain Testing in Multiple Myeloma

Diagnostic Purposes

Testing for kappa light chains helps establish clonality of plasma cells, which is essential for diagnosing multiple myeloma and related disorders, as recommended by the International Myeloma Society 1, 2
Kappa/lambda ratio assessment is crucial for identifying abnormal plasma cell populations, as restricted light chain expression becomes apparent when the monoclonal population exceeds 30% of polyclonal cells, according to the European Hematology Association 2
Testing is recommended for patients with monoclonal gammopathy of undetermined significance (MGUS) to aid in risk stratification and early detection of progression, as suggested by the American Society of Hematology 1

Serum FLC measurements are essential for monitoring response to treatment in multiple myeloma, particularly in light chain myeloma and nonsecretory myeloma, as stated by the National Comprehensive Cancer Network 3

Abnormal FLC ratios help identify patients with higher risk of progression from precursor conditions like MGUS to active multiple myeloma, according to the International Myeloma Society 3

Serum FLC assay should be performed alongside serum protein electrophoresis and immunofixation for comprehensive evaluation, as recommended by the National Comprehensive Cancer Network and the American Society of Hematology 4, 1
When monitoring disease, it's crucial to use the same test for serial studies to ensure accurate relative quantification, as stated by the National Comprehensive Cancer Network 4
Serum FLC assay cannot completely replace 24-hour urine protein electrophoresis for monitoring patients with measurable urinary M-protein, according to the National Comprehensive Cancer Network and the European Hematology Association 4, 3
FLC measurements can be affected by renal function, potentially leading to false elevations, as noted by the American Society of Nephrology 3
At least 100 neoplastic plasma cell events should be acquired for accurate enumeration when using flow cytometry to assess light chain expression, as recommended by the European Hematology Association 2

Testing for kappa light chains is valuable for diagnosing monoclonal gammopathy of renal significance (MGRS), where monoclonal immunoglobulins cause kidney damage, as stated by the American Society of Nephrology 5, 6
Light chain testing helps identify light chain escape, where disease evolves to become oligosecretory, nonsecretory, or light chain-only disease, according to the American Society of Clinical Oncology 7

Urine-free light chain assay should not be performed; instead, 24-hour urine collection for electrophoresis and immunofixation is recommended, as stated by the American Society of Hematology 1
A 24-hour urine collection cannot be replaced by a morning urine sample for accurate assessment, according to the International Myeloma Society 1
Random urine samples with analytes corrected relative to creatinine concentration require further evaluation and cannot be recommended at this point, as noted by the European Hematology Association 1

High free light chain values are associated with various plasma cell disorders including multiple myeloma, light chain myeloma, smoldering multiple myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS) 8

The International Myeloma Working Group incorporates the free light chain ratio into risk stratification models for both MGUS and SMM 9

The National Comprehensive Cancer Network recommends further diagnostic workup including complete serum protein electrophoresis (SPEP) and immunofixation (SIFE) for patients with elevated kappa light chain values 10
The National Comprehensive Cancer Network also recommends bone marrow aspiration and biopsy to assess plasma cell percentage and clonality, as well as skeletal survey or advanced imaging to assess for bone lesions 11
If a plasma cell disorder is diagnosed, risk stratification should be performed using the Revised International Staging System (R-ISS), which incorporates cytogenetics and LDH in addition to traditional markers, as recommended by the European Society for Medical Oncology 12

Serial measurements of free light chains should use the same assay to ensure accurate relative quantification, as recommended by the National Comprehensive Cancer Network 10

Renal impairment can cause decreased clearance of both kappa and lambda free light chains, leading to elevation of both 13
A normal kappa/lambda ratio (0.26-1.65) suggests polyclonal activation or renal impairment, as stated by the International Myeloma Society 14

Elevated free light chains with an abnormal ratio is one of the diagnostic criteria for active (symptomatic) myeloma, according to the National Comprehensive Cancer Network 15
An abnormal serum free light chain ratio ≥100 (involved kappa) or <0.01 (involved lambda) is considered a myeloma-defining event, as defined by the National Comprehensive Cancer Network 15
Light chain MGUS is defined by abnormal FLC ratio, increased level of the appropriate involved light chain, no heavy chain expression, <10% bone marrow plasma cells, and absence of end-organ damage, as stated by the International Myeloma Society 14

A 24-hour urine collection for electrophoresis and immunofixation is recommended when both kappa and lambda free light chains are elevated, as suggested by the National Comprehensive Cancer Network 16
Evaluation of renal function is necessary, as impaired kidney function can cause elevation of both light chains, according to the National Comprehensive Cancer Network 13

For patients with renal impairment due to light chain cast nephropathy, prompt initiation of bortezomib-containing regimens is recommended to decrease production of nephrotoxic clonal immunoglobulin, as recommended by the National Comprehensive Cancer Network 13

Light chain MGUS has the lowest progression risk at only 0.27% per year, substantially lower than conventional MGUS at 1% per year, according to the International Myeloma Society 17, 18
Acute kidney injury from light chain cast nephropathy occurs when serum FLC exceeds 80-200 mg/dL, particularly with high urinary FLC excretion, as reported in the Blood Cancer Journal 19
Rapid reduction of serum FLC by at least 50-60% is essential for renal recovery, with better outcomes when achieved by day 12 versus day 21 of treatment, as stated in the Blood Cancer Journal 19
Even small clones in MGUS cause increased risk of venous and arterial thrombosis, infections, osteoporosis, and bone fractures through bone marrow microenvironment alterations, according to Haematologica 17, 18, 20

Skeletal survey or advanced imaging (MRI or PET-CT) should be performed to assess for bone lesions, as focal lesions predict progression to active myeloma, as recommended by the International Myeloma Society 17